Maryland's Prescription Drug Affordability Board voted Monday to restrict the price that state and local employees will have to pay for two medicines for type 2 diabetes, Jaridance and Farxiga.

Subscribe to continue reading this article.

Already subscribed? To log in, click here.

See Full Page